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Background. New vaccines against tuberculosis (TB) are urgently needed because the only available vaccine,
Mycobacterium bovis bacillus Calmette-Gue ´rin (BCG), fails to protect against pulmonary TB in adults. The
recombinant DureC hly1 BCG (rBCG) is more efﬁcient than parental BCG (pBCG) against pulmonary TB in
preclinical studies and has proven safe and immunogenic in phase I clinical trials.
Methods. In an attempt to identify the mechanisms underlying the superior protection of rBCG, we compared
the immune responses elicited after vaccination and subsequent aerosol infection with Mycobacterium tuberculosis
(MTB) in mice.
Results. We demonstrate that both rBCG and pBCG induce marked type 1 cytokine responses, whereas only
rBCG elicits a profound type 17 cytokine response in addition. We observed earlier recruitment of antigen-speciﬁc
T lymphocytes to the lung upon MTB infection of rBCG-vaccinated mice. These T cells produced abundant type 1
cytokines after restimulation, resulting in 10-fold reduced bacterial burden 90 days after infection.
Conclusions. Our ﬁndings identify a general immunologic pathway for improved vaccination strategies against
TB that can also be harnessed by other vaccine candidates.
Every year, up to 2 million people die from tuberculosis
(TB) [1]. The only available vaccine against TB is
Mycobacterium bovis bacillus Calmette-Gue ´rin (BCG),
which was used in humans for the ﬁrst time in 1921 [2].
To date, 4 billion doses of BCG have been administered,
making it the most widely used human vaccine world-
wide [3]. Yet, we are still far from having achieved
eradication of TB. BCG vaccination prevents tuberculous
meningitis and miliary TB in infants [4]. However,
protection against other forms of TB, notably pulmonary
TB in adolescents and adults, is inconclusive, as em-
phasized by a meta-analysis that revealed protective ef-
ﬁcacies ranging from 0% to 80% [5]. Therefore, new
vaccines against TB are urgently needed. At present, new
vaccination strategies against TB include recombinant
BCG to replace orboost canonical BCG as well as subunit
vaccines andnonreplicatingviral vector-based vaccines to
booster BCG prime [6, 7].
Identiﬁcation of the immunologic mechanisms that
underly protection can facilitate the rational design of
novel vaccination strategies for TB prevention. More-
over, biomarkers indicative for protective immunity
couldserve as surrogateendpointsofclinicaloutcome in
TBvaccine efﬁcacytrialsandthus reducethedurationof
those trials as well as facilitate testing of larger numbers
of vaccine candidates. Observational studies of newly
infected, healthy contacts of patients with TB and
BCG-vaccinated infants have been initiated to deﬁne
such biomarkers [8]. Despite extensive research on the
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memory have yet to be elucidated. After BCG vaccination,
antigen-speciﬁc memory CD4 T cells are difﬁcult to detect
because of the paucity of immunodominant antigens. Cur-
rently, the most widely used biomarkers are based on elevated
frequencies of CD4 T cells producing interferon c (IFN-c).
Increasing evidence questions the value of IFN-c as correlate of
protection in TB [9, 10]. Undoubtedly IFN-c does play a cru-
cial role in defense against Mycobacterium tuberculosis (MTB)
infection [11], but determination of IFN-c levels alone can no
longer be considered a reliable marker of protective immunity.
We constructed a recombinant DureC hly1 BCG (rBCG)
strain that expresses membrane-perforating listeriolysin (hly) of
Listeria monocytogenes a n di sd e v o i do fu r e a s eC .T h i sr B C G
construct induces superior protection against aerogenic challenge
with MTB compared with parental BCG (pBCG) [12]. The rBCG
construct has successfully proven to be safe and immunogenic in
phase I clinical trials. In this study, we compared immune re-
sponses after vaccination with rBCG or pBCG in an attempt to
identify biomarkers that correlate with protection in a mouse
model of TB infection. Our data reveal that rBCG concomitantly
induced a balanced combination of type 1 and type 17 cytokine
responses, whereas pBCG-induced immunity comprised a type 1
response only. The results of further experiments emphasize the
unique role of interleukin (IL) 17 in improved protection against
TB and hence point to general mechanisms for consideration in
future vaccine design against this major health threat.
MATERIALS AND METHODS
Mice
Female BALB/c mice were kept under speciﬁc pathogen-free
conditions. Experiments were conducted with the approval of
the Landesamt fu ¨r Gesundheit und Soziales (State Ofﬁce of
Health and Social Affairs, Berlin, Germany).
Bacteria
The MTB strains H37Rv, pBCG, and rBCG that were used have
been described elsewhere [12]. Bacteria were grown in Mid-
dlebrook 7H9 agar supplementedw i t hg l y c e r o l ,0 . 0 5 %T w e e n8 0 ,
and albumin dextrose catalase. Midlogarithmic cultures were
harvested and stored at –80C. Stocks were titrated prior to use.
Vaccination and MTB Infection
T h ep B C Go rr B C G( 1 0
6 colony-forming units [CFUs]) were
administered subcutaneously. Aerogenic infection was performed
using a Glas-Col inhalation exposure system. Bacterial burdens
were assessed by mechanical disruption of removed organs in
phosphate-buffered saline (PBS)with 0.5%vol/volTween 80and
plating serial dilutions onto Middlebrook 7H11 agar plates sup-
plemented with oleic acid-albumin-dextrose-catalase. Colonies
were counted after 3 weeks.
Cell Isolation, Stimulations, and Flow Cytometry
Cells were puriﬁed as described elsewhere [13]. Cells were
stimulated with 50 lg/mL puriﬁed protein derivative (PPD; SSI)
for 20 hours for analysis by multiplex assay or for 6 hours in the
presence of 25 lg/mL brefeldin A for intracellular cytokine
staining. The following antibodies were used: CD4, IFN-c,I L - 2 ,
Ly6G/C, CD11b, cd-T-cell receptor, and CD49b (eBioscience).
CD8a, tumor necrosis factor a (TNF-a), CD16/CD32, F4/80,
and CD11c were puriﬁed from hybridoma supernatants and
ﬂuorescently labeled. IL-17 was obtained from BD Biosciences.
Cells were analyzed using a FACSCanto II or LSRII and
FACSDiva software (BD Biosciences). Cytokines were measured
using the Bio-Plex Mouse Th1/Th2, IL-17, and IL-6 bead-based
immunoassays (Bio-Rad). IL-21 and IL-22 were measured by
enzyme-linked immunosorbent assay (R&D systems).
Peritoneal Lavage
The pBCG or rBCG was freshly prepared from midlogarithmic
cultures; 10
6 CFUs were administered intraperitoneally. Re-
cruited cells were obtained from the peritoneal cavity by in-
jection of 5 mL PBS and analyzed by ﬂow cytometry. Cytokine
and chemokine levels were determined using the Bio-Plex
Mouse Cytokine 23-plex kit (Bio-Rad).
RESULTS
Type 1 and Type 17 Cytokine Responses After rBCG and pBCG
Vaccination
In an attempt to elucidate the immune mechanisms relevant to
TB vaccine efﬁcacy, we compared immune responses to rBCG
and pBCG in mice. Superior protective efﬁcacy of rBCG had
been originally determined after intravenous immunization
[12]. Subcutaneous administration of rBCG induced compara-
ble levels of protection and retained the superior efﬁcacy of
rBCG over pBCG (Figure 1). We analyzed long-term memory
responses 83 days after subcutaneous vaccination with rBCG
or pBCG. Cells were restimulated with PPD, and supernatants
were analyzed by multiplex assays for cytokines. Immunization
with rBCG induced signiﬁcantly higher cytokine production by
cells isolated from the lung compared with pBCG (Figure 1).
These cytokines included IFN-c, IL-2, IL-6, and granulocyte-
macrophage colony-stimulating factor (GM-CSF). In contrast,
levels of the type 2 cytokines IL-4, IL-5, and IL-10 were not
increased above background levels (data not shown). Intri-
guingly, approximately 3-fold higher IL-17 concentrations were
produced by lung cells from rBCG-vaccinated mice. Note that
only a few cells could be isolated from the lungs of uninfected
mice. Consequently, overall cytokine concentrations in lungs
were lower than those in spleens, where 10-fold higher cell
densities could be used for stimulation (Figure 1). In spleens,
both vaccines elicited equally strong type 1 responses as reﬂected
by comparable concentrations of IL-2, IL-6, IFN-c,a n dG M - C S F .
1574 d JID 2011:204 (15 November) d Desel et alYet, spleen cells from rBCG-vaccinated mice produced signiﬁ-
cantly more IL-17 upon restimulation with PPD compared with
pBCG-vaccinated animals. Thus, immunization with rBCG, but
not pBCG, induced concomitant and strong type 1 and type 17
cytokine responses in lungs and spleens, which were sustained
for prolonged periods.
Enhanced Early Response of MTB-Specific T Cells Upon
Infection With Virulent MTB in rBCG-Vaccinated Mice
T-helper (Th) 17 cells have been linked to improved immune
surveillance [14]. We compared antigen-speciﬁc T-cell responses
in vaccinated animals upon aerosol infection with virulent
MTB, 7 days after infection. Marked production of IFN-c,
IL-17, IL-2, and GM-CSF by lung cells from rBCG-vaccinated
mice was detected 20 hours after restimulation with PPD
(Figure 2). In contrast, these cytokines were barely secreted by
cells from pBCG-vaccinated mice. In nonvaccinated animals
infected with MTB, cytokine production levels were below the
detection limit, in agreement with previous reports that MTB-
speciﬁc T cells do not appear before 3 weeks after MTB in-
fection [14]. Type 2 cytokines IL-4, IL-5, and IL-10 were not
detected, and levels of TNF-a, IL-12p70, and IL-6 were only
Figure 1. Superior protection and cytokine induction by recombinant DureC hly1 bacillus Calmette-Gue ´rin (rBCG) over parental bacillus Calmette-Gue ´rin
(pBCG) vaccination. A, Protection by subcutaneous immunization against infection with Mycobacterium tuberculosis (MTB). Mice were vaccinated 90 days
beforeaerosolinfectionwith200–400colony-formingunits(CFUs)ofMTB,andthebacterialburdenwasdetermined90daysafterinfection.Thecardiaclung
lobewas homogenized; the remaining materialwas usedfor invitro restimulation assays. StatisticalsignificancewasdeterminedbytheMann-Whitney test
with2-tailedP values. *P ,.05;**P ,.01. Data are representativeof3 experimentswithsimilar results.B,C, Responses in lungs and spleens, respectively,
83daysafter subcutaneousvaccination with rBCGorpBCG. A totalof 2.5 3 10
5 cells (lung)or 2 3 10
6 cells (spleen) wererestimulatedwithpurified protein
derivative for 20 hours, and the supernatants were analyzed by multiplex assays. Cytokine concentrations are depicted as means (6 SEM) of 4 independent
experiments with 3 replicates each. Background cytokine production levels from medium controls were subtracted. Analysis of variance and the Bonferroni
multiple comparison test were applied for statistical analysis. *P , .05; **P , .01. Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating
factor; IFN-c,i n t e r f e r o nc; IL-2, interleukin 2; IL-6, interleukin 6; IL-17, interleukin 17; NIL, none; TNF-a, tumor necrosis factor a.
rBCG Induces Balanced Type 1/Type 17 Response d JID 2011:204 (15 November) d 1575Figure 2. Vaccination with recombinant DureC hly1 bacillus Calmette-Gue ´rin (rBCG) confers enhanced early responses of antigen-specific Tcells in the lung
upon aerosol infection with Mycobacterium tuberculosis (MTB). A, Cytokine secretion by lung cells 7 days after aerosol infection with 200–400 colony-forming
units ofMTB. A totalof2 3 10
5c e l l sw e r es t i m u l a t e dw i t hp u r i f i e dp r o t e i nd e r i v a t i v e( P P D )f or20 hours,andthe supernatants wereanalyzedby multiplex assay.
Cytokine concentrations are depicted as means (6 SEM) of 2 independent experiments with 3 replicates each. Background cytokine production levels from
medium controls were subtracted. B, Analysis of cells restimulated with PPD for 6 hours in the presence of brefeldin A by multicolor flow cytometry.
Frequencies of responding CD4 T cells are depicted as means (6 SEM) of 3 independent experiments with 3 replicates each. Analysis of variance and the
Bonferroni multiple comparison test were applied for statistical analysis. *P , .05; **P , .01; ***P , .001. Abbreviations: GM-CSF, granulocyte-
macrophage colony-stimulatingfactor;IFN-c, interferon c; IL-2, interleukin 2; IL-17, interleukin 17; NIL, none; pBCG, parental BCG; TNF-a, tumor necrosis factor a.
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MTB challenge (data not shown).
We determined cytokine production levels by lung T cells by
ﬂow cytometry 7 days after MTB infection (Figure 2). Cells
were stimulated with PPD for 6 hours, followed by intracellular
cytokine staining for IL-2, IL-17, IFN-c, and TNF-a. In non-
vaccinated control mice, a small proportion of CD4 T cells
produced IL-2, TNF-a, or IFN-c. In vaccinated mice, CD4
Figure 3. Vaccination with recombinant DureC hly1 bacillus Calmette-Gue ´rin (rBCG) increases purified protein derivative (PPD)–specific responses in the
spleen upon aerosol infection with Mycobacterium tuberculosis (MTB). A, Cytokine secretion by spleen cells 7 days after aerosol infection with 200–400 colony-
forming units of MTB. A total of 2 3 10
6 c e l l sw e r er e s t i m u l a t e dw i t hP P Df o r2 0h o u r s ,a n dt h es upernatants were analyzed by multiplex assays. Cytokine
concentrations are depicted as means (6 SEM) of 4 independent experiments with 3 replicates each. Background cytokine production levels from medium
controls were subtracted. B, Analysis of cells restimulated with PPD for 6 hours in the presence of brefeldin A by multicolor flow cytometry. Frequencies of
responding CD4 Tcells are depicted as means (6 SEM) of 3 independent experiments with 3 replicates each. Analysis of variance and the Bonferroni
multiple comparison test were applied for statistical analysis. *P ,.05; **P ,.01; ***P ,.001. Abbreviations: GM-CSF, granulocyte-macrophage
colony-stimulating factor; IFN-c, interferon c; IL-2, interleukin 2; IL-17, interleukin 17; NIL, none; pBCG, parental BCG; TNF-a, tumor necrosis factor a.
rBCG Induces Balanced Type 1/Type 17 Response d JID 2011:204 (15 November) d 1577Figure 4. Immune responses in the lung during persistent Mycobacterium tuberculosis (MTB) infection in mice vaccinated with recombinant DureC
hly1 bacillus Calmette-Gue ´rin (rBCG). A, Cytokine secretion by lung cells 90 days after aerosol infection with 200–400 colony-forming units of MTB. Cells
were restimulated with purified protein derivative (PPD) for 20 hours, and the supernatants were analyzed by multiplex assays. Cytokine concentrations
are depicted as means (6 SEM) of 2 independent experiments with 3 replicates each. Background cytokine production levels from medium controls were
subtracted. B, Analysis of cells restimulated with PPD for 6 hours in the presence of brefeldin A by multicolor flow cytometry. Frequencies of responding
CD4 T cells are depicted as means (6 SEM) of 2 independent experiments with 3 replicates each. Analysis of variance and the Bonferroni multiple
comparison test were applied for statistical analysis. *P ,.05; **P ,.01. Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor;
IFN-c, interferon c; IL-2, interleukin 2; IL-6, interleukin 6; IL-17, interleukin 17; NIL, none; pBCG, parental BCG; TNF-a, tumor necrosis factor a.
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of single-cytokine-producing cells were highest, albeit not sig-
niﬁcant, in the rBCG group. In vaccinated animals, we detected
multifunctional T cells, which are implicated in protective
immunity [15]. Multiple-cytokine–producing T cells were pre-
dominantly IL-2
1TNF-a
1 double producers, and levels were
signiﬁcantly increased upon rBCG vaccination. Triple-producer




levels were slightly increased in rBCG-vaccinated mice com-





1 quadruple-positive cells exclusively
appeared in the rBCG group, albeit at very low frequencies.
Splenic T cells produced similar cytokine patterns to those
of pulmonary T cells (Figure 3). IL-2 and GM-CSF production
was signiﬁcantly higher in rBCG-vaccinated animals than in
pBCG-vaccinated animals and below the detection level in
nonvaccinated controls, even though a small percentage of CD4
T cells produced IFN-c in nonvaccinated controls. In sum,
vaccination with either pBCG or rBCG induced CD4 T cells
secreting IFN-c and TNF-a withhigherfrequenciesofsingleand
multiple producers in rBCG-vaccinated mice compared with
pBCG-vaccinated mice. This is consistent with the ﬁnding that
IL-17 accelerates recruitment of IFN-c–producing cells to the
site ofinfection [14]. Different levelsof cytokine production and
frequencies of producer cells were not due to different bacterial
burdens, as conﬁrmed bycomparable numbers of CFUsin lungs
and spleens (data not shown). Total numbers of T-regulatory
cells increased upon infection to a comparable degree in
Figure 5. Vaccination with recombinant DureC hly1 bacillus Calmette-Gue ´rin (rBCG) induces production of interleukin (IL) 22 but not IL-21. A, B, IL-21
and IL-22 secretion, respectively, by cells from spleens (2 3 10
6 cells) or lungs (2 3 10
5 cells) of mice 83 days after vaccination and subsequent aerosol
infection with 200–400 colony-forming units of Mycobacterium tuberculosis. IL-21 concentrations were measured from 3 samples per group; means
(6 SEM) are depicted. For IL-22, samples from 1 group were pooled. Data are representative of 2 (day 83 after vaccination) and 5 (day 7 after infection)
similar experiments. Cells were restimulated with purified protein derivative (PPD) for 20 hours, and the supernatants were analyzed by enzyme-linked
immunosorbent assay. Abbreviations: NIL, none; pBCG, parental BCG; RPMI, Roswell Park Memorial Institute medium.
rBCG Induces Balanced Type 1/Type 17 Response d JID 2011:204 (15 November) d 1579Figure 6. Recombinant DureC hly1 bacillus Calmette-Gue ´rin (rBCG) causes increased recruitment of cd T cells and natural killer (NK) cells without
significantly altering antigen-presenting cell (APC) populations. A, Analysis of cell populations in peritoneal lavage fluid by flow cytometry. Cells were
recruited to the peritoneal cavity upon intraperitoneal administration of 10
6 colony-forming units of rBCG or parental BCG (pBCG). APCs were harvested
1580 d JID 2011:204 (15 November) d Desel et alvaccinated groups (data not shown). At 7 days after infection,
CD4 T cells were the main cytokine producers; cytokine-pro-
ducing CD8 T cells were detected with lower frequencies in
lungs and spleens albeit with similar patterns (data not shown).
Vaccination With rBCG Confers Potent Immune Responses
During Persistent Infection
We analyzed MTB-speciﬁc immune responses 90 days after in-
fection,whenlungbacterialburdenswereapproximately10-fold
lower inrBCG-immunizedanimalsthaninthepBCGgroupand
100-fold lower than in nonvaccinated controls. Cells from lungs
of vaccinated mice and untreated controls were restimulated
with PPD for 20 hours, and cytokine concentrations were
measured by multiplex assays (Figure 4). Cytokines detected
upon restimulation were predominantly of type 1. However, we
could not detect differences in IFN-c or IL-17 levels between the
2 vaccinated groups during persistent infection. In contrast,
amounts of IL-2, IL-6, GM-CSF, and TNF-a were higher in
rBCG-vaccinated mice. In all groups, IL-4 and IL-5 levels were
below the detection limit (data not shown). In addition, analysis
of lung cells by multicolor ﬂow cytometry revealed pre-
dominantly cytokine-producing CD4 T cells during persistent
infection (Figure 4). CD4 T cells secreting only IFN-c were
detected in all groups with similar frequencies. Upon vaccina-
tion, CD4 T cells producing IL-2, IFN-c,T N F - a,o rI L - 1 7i n
different combinations could also be detected. Intriguingly,
frequencies ofresponding CD4 T cells didnot differsigniﬁcantly
between rBCG- and pBCG-vaccinated mice despite higher
concentrations of IL-2 and TNF-a in supernatants. We assume
that both vaccines increased frequencies of antigen-speciﬁc CD4
T cells in the lung during persistent MTB infection, with rBCG-
induced T cells becoming more potent cytokine producers. CD8
T cells almost exclusively secreted IFN-c with comparable fre-
quencies in all groups, and multifunctional CD8 T-cell counts
were barely above the background (data not shown).
Vaccination Causes IL-22 but Not IL-21 Production
Th17 cells can produce additional effector cytokines such as
IL-21 [16] and IL-22 [17]. IL-22–producing cells have been
identiﬁed in patients with TB, but these cells seem to be distinct
from IL-17–producing cells [18]. We did not detect IL-21 after
PPD stimulation of cells from vaccinated and subsequently
MTB-infected mice (Figure 5). IL-22 was produced at elevated
concentrations by PPD-stimulated splenocytes (Figure 5)i ni m -
munized mice, but concentrations did not further increase early
after infection with MTB. IL-22 production by lung cells was
only observed in the rBCG-vaccinated group and decreased after
aerosol MTB infection.
rBCG Causes Increased Recruitment of gd T Cells and Natural
Killer Cells Without Significantly Altering Antigen-Presenting
Cell Populations
We wanted to better understand the mechanisms underlying
IL-17 induction after immunization with rBCG. To this end,
rBCG and pBCG were administered intraperitoneally, and im-
migrant cells were isolated from the peritoneal cavity 5 hours
or 6 days after administration and analyzed by ﬂow cytometry.
Neutrophils (deﬁned as Gr1
high,C D 1 1 b
high,M H C I I
2,a n d
CD11c
2) rapidly entered the peritoneal cavity and remained at
elevated counts on day 6 after infection in the pBCG and rBCG
groups to the same extent. Frequencies of peritoneal macro-
phages (deﬁned as CD11b
high, F4/80
high,G r 1
2,M H C I I
high,a n d
CD11c
2) and dendritic cells (deﬁned as CD11c
1,C D 1 1 b
lo,a n d
Gr1
2) remained unchanged. In sum, no signiﬁcant differences
in antigen-presenting cell (APC) recruitment were detectable
between the rBCG and pBCG groups (Figure 6).
Peritoneal cells harvested 5 hours after vaccination were
subjected to polyclonal stimulation (Figure 6)w i t haCD3/
aCD28 antibodies. Frequencies of CD4 T cells and natural killer
(NK) cells were comparable between all groups, as were levels of
IFN-c andIL-17 production.Six daysafteradministration,these
cells increased numerically and reached the highest frequencies
intherBCGgroup(Figure6).PPDwasusedforrestimulationof
cells on day 6. CD4 T cells did not produce appreciable amounts
of IFN-c or IL-17, whereas a substantial proportion of NK cells
produced IFN-c after rBCG administration. The cd T cells have
been identiﬁed as a major source of early IL-17 in TB [19].
Increased, albeit not signiﬁcant, proportions of cd T cells pro-
ducing IFN-c were identiﬁed 5 hours after administration of
rBCG. This cell population further increased numerically, and
markedly higher frequencies of cd T cells producing IL-17 were
detected in the rBCG group 6 days after vaccination. CD8 T cells
were not detected in the peritoneal cavity in any of the groups.
In addition, we analyzed cytokines and chemokines in the
from the peritoneum 5 hours (upper panel) and 6 days (lower panel) after intraperitoneal administration of rBCG or pBCG. B,
Intracellular cytokine staining (ICS) of T-cell populations 5 hours after injection. Cells were stimulated with aCD3/aCD28 antibodies for 18 hours in the
presence of brefeldin A. C, ICS of T-cell populations 6 days after administration. Cells were restimulated with purified protein derivative for 18 hours in
the presence of brefeldin A. Data are presented as a summary of 3 independent experiments with 5 mice per group. Horizontal lines indicate the median
values. Analysis of variance and the Bonferroni multiple comparison test were applied for statistical analysis. *P ,.05; **P ,.01. D, Cytokines and
chemokines detected in peritoneal lavage fluid analyzed by multiplex assay, depicted as mean concentrations (6 SEM); summary of 3 independent
experiments with 5 mice per group. Abbreviations: DC, dendritic cells; G-CSF, granulocyte colony-stimulating factor; IFN-c,i n t e r f e r o nc; IL-12p40, interleukin
12p40; IL-17, interleukin 17; KC, keratinocyte chemoattractant; MCP-1, monocyte chemoattractant protein-1; MIP-1a, macrophage inflammatory protein-1a;
PBS, phosphate-buffered saline.
Figure 6 continued.
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(Figure 6). Levels of monocyte chemoattractant protein (MCP)-1,
macrophage inﬂammatory protein (MIP)-1a, granulocyte
colony-stimulating factor (G-CSF), and keratinocyte chemo-
attractant (KC) were rapidly increased upon injection; levels of
eotaxin remained unchanged and IL-12p40 was detected in
higher concentrations after 6 days. However, we could not
detect any signiﬁcant differences in these measures between the
pBCG and rBCG groups. Levels of IL-1b, IL-6, IL-9, IL-13,
MIP-1b, and regulated upon activation, normal T-cell ex-
pressed and secreted could also be measured in comparable
concentrations, whereas IL-12p70, IFN-c,I L - 1 a,I L - 2 ,I L - 3 ,
IL-4, IL-5, IL-10, IL-17, GM-CSF, and TNF-a concentrations
were below the detection limit (data not shown). Thus, rBCG
and pBCG induced recruitment of APCs as well as chemo-
kine and cytokine production at the site of administration to
a similar extent. Intriguingly, proportions of cd T cells se-
creting IL-17 and NK cells producing IFN-c were most
abundant after rBCG administration.
DISCUSSION
The identiﬁcation of biomarkers is crucial for rational design of
novel TB vaccines. These markers could also form the basis for
deﬁnition of surrogate markers to predict endpoints of clinical
outcome in TB vaccine efﬁcacy trials and thus provide guide-
lines for improvement of current vaccine candidates. The im-
portance of key cytokines that activate macrophage
antimycobacterial capacities including IFN-c [20] and TNF-a
[21], and the necessity for IL-2 in the expansion of memory cells
[22], are well established and thus commonly used to monitor
TB vaccine trials.
In an attempt to better understand immune mechanisms
underlying the superior protection of rBCG over pBCG and to
harness our knowledge for identiﬁcation of biomarkers of vac-
cine efﬁcacy, we compared long-term memory immune re-
sponses elicited by rBCG and its parental strain, pBCG.
Responses differed in both quantitative and qualitative terms.
We detected an increased abundance of type 1 cytokines as well
as IL-17 in the lung following vaccination with rBCG. Analysis
of vaccine-induced immune responses in the lungs is obviously
not feasible in the context of clinical trials. Therefore, we also
analyzed systemic long-term memory responses. Intriguingly,
comparable concentrations of type 1 promoting cytokines were
detected in both pBCG and rBCG groups. In contrast, IL-17
production by splenocytes was signiﬁcantly elevated upon rBCG
vaccination. Thus, we conclude that the systemic release of IL-
17, rather than of IFN-c or IL-2, qualiﬁed as a potential marker
of superior protection induced by rBCG.
Th17 cells contribute to antimicrobial defense by attracting
and activating neutrophils [23], which are among the ﬁrst cells
recruited in response to IL-17. It has been shown that IL-17 is
dispensable during primary MTB infection [24, 25] but gains
importance in memory responses [14]. In addition, recent re-
ports on the expression of CCR6 on human Th17 cells [26, 27]
point to a positive feedback loop, because CCR6 is the receptor
for CCL20 produced by neutrophils [28] and CCL20-CCR6 has
been implicated in immunopathogenesis of TB [29]. Thus, type
17 cytokines could promote enhanced recruitment of antigen-
speciﬁc memory T cells to the sites of bacterial residence.
Analysis of vaccine-induced immune responses 7 days after in-
fection with MTB revealed that vaccination with rBCG indeed
led to an enhanced early response of effector cells at the sites
of bacterial replication. We observed increased frequencies of
antigen-speciﬁc CD4 T cells and elevated production of IL-2,
IL-17, IFN-c, and GM-CSF by lung and spleen cells. Multi-
functional CD4 T cells coproducing IL-2, IFN-c, and TNF-a
were ﬁrst implicated in successful vaccination strategies against
Leishmania major [15] and later also against MTB [30]. Re-
cently, these polyfunctional CD4 T cells were also detected in TB
vaccine trials [31, 32]. We detected polyfunctional CD4 T cells
upon rBCG and pBCG vaccination and subsequent infection;
however, the composition of cytokines (IL-2, IL-17, IFN-c,a n d
TNF-a) in double and triple producers varied considerably
between experiments as well as between individual animals. If
multifunctional cells were a true correlate of protection, then
their overall frequencies, which were higher in the rBCG group,
rather than their composition, seem relevant.
Th17 cells are considered to be instrumental in inﬂammatory
andautoimmunediseasessuchascollagen-inducedarthritis[33],
experimental autoimmune encephalomyelitis (EAE) [33, 34],
and allergic airway hypersensitivity [33, 35]. This pathogenic
role is usually associated with development of a profound
IL-21–mediated inﬂammatory response. We never detected
IL-21 after vaccination and subsequent MTB infection above
background levels (data not shown). A recent report described
a pathological role for IL-17 after repeated BCG vaccination
and MTB exposure [36]. In contrast, the single administration
of rBCG described here elicited a balanced type 1/type 17 cy-
tokine response, and increased IL-17 abundance was only de-
tected prior to and early after MTB infection. During persistent
infection, IFN-c and IL-17 production was comparable be-
tween the pBCG and rBCG groups. In addition, we never ob-
served signs of autoimmunity or excessive inﬂammation upon
vaccination with rBCG for up to 200 days after MTB infection.
In an attempt to compare data from mouse experiments
with data from human studies, we analyzed cytokine proﬁles of
frozen peripheral blood mononuclear cells from a phase I clin-
ical trial with rBCG and pBCG. In a limited number of samples
(3 samples from pBCG-vaccinated donors and 7 samples from
rBCG-vaccinated donors), we detected IL-17 production after
rBCG vaccination but not after pBCG vaccination (data not
shown). Th17 cells have been detected in peripheral blood
samples from MTB-infected humans [18]. Recently, IL-17–
1582 d JID 2011:204 (15 November) d Desel et alproducing CD4 T cells have been reported in samples from
adolescents vaccinated with a modiﬁed vaccinia virus Ankara
expressingAg85A[32,37].Thus,itistemptingtoconsiderIL-17
as a correlate of protection in TB vaccine trials.
Why did rBCG but not pBCG induce IL-17 production?
Immunization with rBCG and pBCG caused recruitment of
APC as well as chemokine and cytokine producers to a similar
extent. Intriguingly, proportions of cd T cells secreting IL-17
and NK cells producing IFN-c were highly abundant after rBCG
vaccination. This is consistent with reports that IL-17 is rapidly
produced by cd Tc e l l s[ 19, 38]a sw e l la sN KTc e l l s[ 39]. NK
cells, counts of which were also increased upon vaccination with
rBCG, are an important early source of IFN-c. These initial
events could pave the way for the development of a sustained,
long-lived memory T-cell response.
We have shown elsewhere that components released from
rBCG reside in the cytosol of infected macrophages [12]. Thus,
rBCG-derived pathogen-associated molecular patterns could
activate intracellular signaling cascades. Nucleotide-binding
oligomerization domain (NOD)-2, for example, is a cyto-
solic pattern recognition receptor and its engagement has been
linked to the development of type 17 memory T-cell responses
[40]. It is further known that apoptosis induced during bacterial
infection promotes generation of Th17 cells [41]. We have ob-
tained evidence that rBCG induces increased apoptosis com-
pared with pBCG [12], which could contribute to increased
development of IL-17–producing T cells. Activation of in-
ﬂammasomes could also contribute to type 17 responses via
production of IL-1b [42]. NOD-like receptor family, pyrin
domain-containing 3, for example, has been found to sense
the presence of listeriolysin through changes in adenosine tri-
phosphate concentrations [43]. Thus, induction of IL-17 se-
cretion could require a complex interplay of intracellular
stimuli and increased apoptosis that are induced upon rBCG
but not pBCG vaccination.
In summary, we demonstrate that vaccination with rBCG
leads to generation of type 17 cytokine production in addition to
profound type 1 cytokine production. The IL-17 produced could
enhance recruitment of antigen-speciﬁc T cells to the lung. Ulti-
mately, this cascade of events results in earlier containment of
MTB and hence to superior protection by rBCG compared with
pBCG. Because IL-17 seems to be instrumental for enhanced re-
cruitment of antigen-speciﬁc T cells to the sites of MTB replica-
tion, future TB vaccines should be tailored to concomitantly
induce balanced type 1 and type 17 cytokine responses.
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